decitabine

Also known as 5-azadeoxycytidine, azadC, DAC, Dacogen®, 4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one, 5'-aza-2'-deoxycytidine, 5-aza-2'deoxycytidine

Decitabine (i.e., 5-aza-2′-deoxycytidine), sold under the brand name Dacogen among others, acts as a nucleic acid synthesis inhibitor. It is a medication for the treatment of myelodysplastic syndromes, a class of conditions where certain blood cells are dysfunctional, and for acute myeloid leukemia (AML). Chemically, it is a cytidine analog.

Research

5,587 papers

Decitabine/Cedazuridine: First Approval.Drugs · 2020
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.The Lancet. Haematology · 2024
Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia.Blood · 2021
Decitabine.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2014
Decitabine.Current opinion in oncology · 2003

via PubMed

Wikidata facts

Mass: 228.085855

Show 5 more facts

chemical formula: C₈H₁₂N₄O₄
isomeric SMILES: C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)CO)O
canonical SMILES: C1C(C(OC1N2C=NC(=NC2=O)N)CO)O
World Health Organisation international non-proprietary name: decitabine
Commons category: Decitabine

Sources (5)

via Wikidata · CC0

~3 min read

Article

6 sections

Contents

Medical uses
Pharmacology
Research
Atherosclerosis
References
Further reading

==Medical uses== Decitabine is used to treat myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System groups. In patients with chronic kidney disease, Batty and colleagues reported the first case series on the feasibility of therapy with hypomethylating agents in patients with chronic kidney disease.